DE60014212D1 - Verfahren zur Herstellung von Substanzen zur Förderung der Sekretion des Wachstumsharmones - Google Patents

Verfahren zur Herstellung von Substanzen zur Förderung der Sekretion des Wachstumsharmones

Info

Publication number
DE60014212D1
DE60014212D1 DE60014212T DE60014212T DE60014212D1 DE 60014212 D1 DE60014212 D1 DE 60014212D1 DE 60014212 T DE60014212 T DE 60014212T DE 60014212 T DE60014212 T DE 60014212T DE 60014212 D1 DE60014212 D1 DE 60014212D1
Authority
DE
Germany
Prior art keywords
substances
preparation
growth hormone
promoting secretion
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60014212T
Other languages
English (en)
Other versions
DE60014212T2 (de
Inventor
Frank Robert Busch
Charles Kwok-Fung Chiu
Clifford Nathaniel Meltz
Ronald James Post
Peter Robert Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60014212D1 publication Critical patent/DE60014212D1/de
Publication of DE60014212T2 publication Critical patent/DE60014212T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60014212T 1999-02-26 2000-02-25 Verfahren zur Herstellung von Substanzen zur Förderung der Sekretion des Wachstumsharmones Expired - Lifetime DE60014212T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12274599P 1999-02-26 1999-02-26
US122745P 1999-02-26

Publications (2)

Publication Number Publication Date
DE60014212D1 true DE60014212D1 (de) 2004-11-04
DE60014212T2 DE60014212T2 (de) 2005-12-15

Family

ID=22404505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60014212T Expired - Lifetime DE60014212T2 (de) 1999-02-26 2000-02-25 Verfahren zur Herstellung von Substanzen zur Förderung der Sekretion des Wachstumsharmones

Country Status (44)

Country Link
US (2) US6541634B2 (de)
EP (2) EP1031575B1 (de)
JP (3) JP3437813B2 (de)
KR (2) KR100372063B1 (de)
CN (3) CN1837205A (de)
AP (1) AP1221A (de)
AR (2) AR029617A1 (de)
AT (1) ATE277944T1 (de)
AU (1) AU764122B2 (de)
BG (1) BG104175A (de)
BR (2) BRPI0000967B8 (de)
CA (1) CA2299495C (de)
CO (1) CO5160252A1 (de)
DE (1) DE60014212T2 (de)
DK (1) DK1031575T3 (de)
DZ (1) DZ3018A1 (de)
EA (1) EA003218B1 (de)
EE (1) EE200000193A (de)
ES (1) ES2226712T3 (de)
GT (1) GT200000018A (de)
HK (1) HK1030219A1 (de)
HN (1) HN2000000021A (de)
HR (1) HRP20000103A2 (de)
HU (1) HUP0000907A3 (de)
ID (1) ID24861A (de)
IL (2) IL134599A (de)
IN (1) IN192352B (de)
IS (1) IS5380A (de)
MA (1) MA25072A1 (de)
NO (1) NO20000965L (de)
NZ (1) NZ503062A (de)
OA (1) OA11325A (de)
PA (1) PA8491201A1 (de)
PE (1) PE20001550A1 (de)
PL (1) PL338628A1 (de)
PT (1) PT1031575E (de)
SG (1) SG90096A1 (de)
SI (1) SI1031575T1 (de)
SK (1) SK284982B6 (de)
TN (1) TNSN00035A1 (de)
TR (1) TR200000536A2 (de)
TW (2) TWI286142B (de)
UA (1) UA70306C2 (de)
ZA (1) ZA200000888B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132388A3 (de) * 2000-03-09 2004-03-03 Pfizer Products Inc. Metaboliten von Hexahydropyrazolo[4,3-c]pyridinen
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
WO2004103983A1 (en) * 2003-05-26 2004-12-02 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US9117477B2 (en) 2013-05-08 2015-08-25 HGST Netherlands B.V. Perpendicular magnetic recording media having novel seed layer
US9499543B2 (en) * 2013-05-28 2016-11-22 Raqualia Pharma Inc. Polymorph forms
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5609150A (en) 1995-04-18 1997-03-11 Maged; Jeffrey M. Method for dilating respiratory passages
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
AU2722297A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
EP1001970B1 (de) 1997-06-25 2007-03-07 Pfizer Inc. Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
PA8491201A1 (es) 2001-04-30
EP1031575A1 (de) 2000-08-30
DK1031575T3 (da) 2005-01-03
NZ503062A (en) 2001-07-27
AR053722A2 (es) 2007-05-16
HUP0000907A3 (en) 2001-05-28
BG104175A (bg) 2000-12-29
BRPI0000967A (pt) 2001-09-11
AR029617A1 (es) 2003-07-10
IN192352B (de) 2004-04-10
CN1270960A (zh) 2000-10-25
SK2302000A3 (en) 2000-11-07
ZA200000888B (en) 2001-08-23
AU1947100A (en) 2000-08-31
JP4051314B2 (ja) 2008-02-20
MA25072A1 (fr) 2000-10-01
HN2000000021A (es) 2001-02-02
BRPI0017522A2 (de) 2009-12-22
TW200718702A (en) 2007-05-16
KR100361783B1 (ko) 2002-11-22
CN1515570A (zh) 2004-07-28
EA200000172A3 (ru) 2000-10-30
PT1031575E (pt) 2004-11-30
CO5160252A1 (es) 2002-05-30
DE60014212T2 (de) 2005-12-15
CN1837205A (zh) 2006-09-27
TNSN00035A1 (fr) 2005-11-10
KR100372063B1 (ko) 2003-02-14
TR200000536A2 (tr) 2000-09-21
SG90096A1 (en) 2002-07-23
EE200000193A (et) 2000-10-16
EP1031575B1 (de) 2004-09-29
HU0000907D0 (en) 2000-04-28
ES2226712T3 (es) 2005-04-01
CA2299495C (en) 2010-06-15
HUP0000907A2 (en) 2001-03-28
US6541634B2 (en) 2003-04-01
AP1221A (en) 2003-11-03
PL338628A1 (en) 2000-08-28
EA200000172A2 (ru) 2000-08-28
GT200000018A (es) 2001-08-16
OA11325A (en) 2003-10-27
US20030158414A1 (en) 2003-08-21
ATE277944T1 (de) 2004-10-15
KR20020065455A (ko) 2002-08-13
BRPI0000967B1 (pt) 2012-06-12
EP1449842A1 (de) 2004-08-25
AP2000001754A0 (en) 2000-03-31
CA2299495A1 (en) 2000-08-26
SI1031575T1 (en) 2005-02-28
SK284982B6 (sk) 2006-03-02
CN1137891C (zh) 2004-02-11
PE20001550A1 (es) 2001-01-11
ID24861A (id) 2000-08-31
JP2000247974A (ja) 2000-09-12
NO20000965L (no) 2000-08-28
DZ3018A1 (fr) 2004-03-20
BRPI0000967B8 (pt) 2021-12-07
BRPI0017522B8 (pt) 2021-05-25
EA003218B1 (ru) 2003-02-27
UA70306C2 (en) 2004-10-15
US6673929B2 (en) 2004-01-06
BRPI0017522B1 (pt) 2013-09-24
JP2003327585A (ja) 2003-11-19
JP3437813B2 (ja) 2003-08-18
JP2003261565A (ja) 2003-09-19
TWI286142B (en) 2007-09-01
IL157103A (en) 2007-07-24
IS5380A (is) 2000-08-27
IL134599A0 (en) 2001-04-30
HK1030219A1 (en) 2001-04-27
IL134599A (en) 2006-12-10
HRP20000103A2 (en) 2001-04-30
IL157103A0 (en) 2004-02-08
AU764122B2 (en) 2003-08-07
KR20010006698A (ko) 2001-01-26
US20020002283A1 (en) 2002-01-03
NO20000965D0 (no) 2000-02-25

Similar Documents

Publication Publication Date Title
DE19983486T1 (de) Verfahren zur Herstellung von Citalopram
DE69906389D1 (de) Verfahren zur herstellung von citalopram
DE69901371D1 (de) Verfahren zur Herstellung von Polyamiden auf Siloxanbasis
DE60035029D1 (de) Verfahren zur herstellung von furfural
DE60125747D1 (de) Verfahren zur herstellung von 2-halobenzoesäuren
DE60141788D1 (de) Verfahren zur Herstellung von epsilon-Caprolactam
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
DE69907056T2 (de) Verfahren zur Herstellung von Benzoesäuren
DE50001310D1 (de) Verfahren zur Herstellung von Iridiumacetat
DE60008830D1 (de) Verfahren zur Herstellung von keramischen Zusammensetzungen
DE60001015D1 (de) Verfahren zur Herstellung von Canthaxanthin
DE60024372D1 (de) Verfahren zur Herstellung von Tetraorganooxysilanen
DE60014212D1 (de) Verfahren zur Herstellung von Substanzen zur Förderung der Sekretion des Wachstumsharmones
DE60025082D1 (de) Verfahren zur kontinuierlichen Herstellung von Chinacridonen
DE69935355D1 (de) Verfahren zur Herstellung von Citalopram
DE59905990D1 (de) Verfahren zur Herstellung von Trifluorbenzoesäuren
DE69903398D1 (de) Verfahren zur Herstellung von 2-Alkyl-3-hydroxybenzoesäuren
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin
DE60031231D1 (de) Verfahren zur Herstellung von 2-Alkyl-4-Isothiazolin-3-onen
DE60004119D1 (de) Verfahren zur Herstellung von Pentaacetyl-beta-D-Glucopyranose
DE60043610D1 (de) Verfahren zur herstellung von l-lysin
DE50003603D1 (de) Verfahren zur Herstellung von Bistrifluormethylbenzylaminen
DE60019763D1 (de) Verfahren zur herstellung von thiazolderivaten
DE60032308T8 (de) Verfahren zur Herstellung von Trichloressigsäure
DE50001772D1 (de) Verfahren zur Herstellung von Nitrodiphenylaminen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: RAQUALIA PHARMA INC., AICHI-KEN, JP